Indeed, erastin treatment leads to significant depletion of intracellular GSH, as detected using traditional biochemical methods and more advanced metabolomics analyses [6, 7, 28]
Care 7 , e000613 (2019)
Case This is a 44-year-old woman who presented in 2017 for evaluation of breast cancer-related lymphedema due to arm swelling
NativePath contains specifically Type I and Type III peptides
Apart from its unclear safety profile in clinical research, we can conclude, based on our dealings with prescribers, that KPV administered subcutaneously can cause certain side effects that are common to most therapeutic peptide injectables: injection site reactions and mild, transient flu-like symptoms
FDA-APPROVED INDICATIONS Type 2 diabetes As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus Limitations of use: has not been studied in patients with a history of pancreatitis TYPE 2 DIABETES RCT SURPASS-2 trial - Tirzepatide vs Semaglutide in Patients with Type 2 Diabetes, NEJM (2021) [PubMed abstract] The SURPASS-2 trial enrolled 1879 adults with type 2 diabetes who were inadequately controlled with metformin at a dose of at least 1500 mg per day Main inclusion criteria Age 18 years T2DM uncontrolled with metformin at 1500 mg/day A1C of 7 - 10.5% BMI 25 and stable for 3 months Main exclusion criteria Type 1 diabetes GFR 50 ng/L
